HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements

TUCSON, Ariz., June 22, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe. HTG has now signed EAP agreements with customers in both the US and Europe and continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.Continue reading

NAU Welcomes a New President

As the 17th president of NAU, José Luis Cruz Rivera has spent time talking with faculty, staff, students and community members, working with university leaders to plan for the fall semester and officially introducing himself and discussing his vision for the university.Continue reading